| Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains TJ Stuhlmiller, SM Miller, JS Zawistowski, K Nakamura, AS Beltran, ... Cell reports 11 (3), 390-404, 2015 | 336 | 2015 |
| Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex JS Zawistowski, SM Bevill, DR Goulet, TJ Stuhlmiller, AS Beltran, ... Cancer discovery 7 (3), 302-321, 2017 | 150 | 2017 |
| Role of HGF in epithelial–stromal cell interactions during progression from benign breast disease to ductal carcinoma in situ P Casbas-Hernandez, M D’Arcy, E Roman-Perez, HA Brauer, ... Breast Cancer Research 15, 1-14, 2013 | 49 | 2013 |
| GSK2801, a BAZ2/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer SM Bevill, JF Olivares-Quintero, N Sciaky, BT Golitz, D Singh, AS Beltran, ... Molecular Cancer Research 17 (7), 1503-1518, 2019 | 46 | 2019 |
| Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer AED Van Swearingen, MJ Sambade, MB Siegel, S Sud, RS McNeill, ... Neuro-oncology 19 (11), 1481-1493, 2017 | 38 | 2017 |
| Extended-representation bisulfite sequencing of gene regulatory elements in multiplexed samples and single cells SJ Shareef, SM Bevill, AT Raman, MJ Aryee, P van Galen, V Hovestadt, ... Nature biotechnology 39 (9), 1086-1094, 2021 | 33 | 2021 |
| Proteomic analysis defines kinase taxonomies specific for subtypes of breast cancer KAL Collins, TJ Stuhlmiller, JS Zawistowski, MP East, TT Pham, CR Hall, ... Oncotarget 9 (21), 15480, 2018 | 28 | 2018 |
| Targeting the breast cancer kinome SM Miller, DR Goulet, GL Johnson Journal of Cellular Physiology 232 (1), 53-60, 2017 | 28 | 2017 |
| Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex. Cancer Discov. 2017; 7: 302–321. doi: 10.1158/2159-8290 JS Zawistowski, SM Bevill, DR Goulet, TJ Stuhlmiller, AS Beltran, ... CD-16-0653.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 28 | |
| Weight loss reduces basal-like breast cancer through kinome reprogramming Y Qin, S Sundaram, L Essaid, X Chen, SM Miller, F Yan, DB Darr, ... Cancer cell international 16, 1-13, 2016 | 22 | 2016 |
| FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036 SP Angus, TJ Stuhlmiller, G Mehta, SM Bevill, DR Goulet, ... NPJ Breast cancer 7 (1), 51, 2021 | 15 | 2021 |
| Systematic analysis of F-box proteins reveals a new branch of the yeast mating pathway N Rangarajan, CL Gordy, L Askew, SM Bevill, TC Elston, B Errede, ... Journal of Biological Chemistry 294 (40), 14717-14731, 2019 | 8 | 2019 |
| Epigenetic inhibition of adaptive bypass responses to lapatinib by targeting BET Bromodomains TJ Stuhlmiller, SM Miller, GL Johnson Molecular & Cellular Oncology 3 (1), e1052182, 2016 | 6 | 2016 |
| Discrete adaptive responses to MEK inhibitor in subpopulations of triple-negative breast cancer DR Goulet, JP Foster, JS Zawistowski, SM Bevill, MP Noël, ... Molecular Cancer Research 18 (11), 1685-1698, 2020 | 5 | 2020 |
| Chromatin complex dependencies reveal targeting opportunities in leukemia FJ Najm, P DeWeirdt, MM Moore, SM Bevill, CA El Farran, KA Macias, ... Nature Communications 14 (1), 448, 2023 | 3 | 2023 |
| Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1/2 inhibition in triple-negative breast cancer SM Bevill, JS Zawistowski, GL Johnson Molecular & cellular oncology 4 (6), e1300622, 2017 | 3 | 2017 |
| Novel synergistic combination therapies with BET bromodomain inhibitors in triple-negative breast cancer. SM Bevill, N Sciaky, BT Golitz, NU Rashid, JS Zawistowski, GL Johnson MOLECULAR CANCER RESEARCH 16 (8), 80-80, 2018 | 1 | 2018 |
| Transcriptional Adaptation to Targeted Inhibitors via BET Bromodomain Proteins in Triple-negative Breast Cancer SM Bevill The University of North Carolina at Chapel Hill, 2018 | 1 | 2018 |
| Pharmacologic targeting of drug-induced enhancers JS Zawistowski, SM Bevill, GL Johnson Oncoscience 4 (5-6), 43, 2017 | 1 | 2017 |
| Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma SM Bevill, S Casaní-Galdón, CA El Farran, EG Cytrynbaum, KA Macias, ... Cell Genomics 3 (7), 2023 | | 2023 |
